Payment overview · 2025
General Payments
$534.78
25 reported records · 14 companies
Healthcare provider profile · identity verified
R Scott Mills, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARIETTA, GA · NPI 1407848716
Verified facts
What the public records show
CMS Open Payments records show R Scott Mills, MD received $534.78 in general payments during 2025 across 25 reported records.
PFIZER INC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Xembify.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xembify as an associated drug or biological on 5209 records involving 2197 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xembify by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $124.15 | 23.2% | 5 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.88 | 11.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.46 | 10.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.90 | 10.1% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.10 | 9.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.16 | 5.6% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $29.75 | 5.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.57 | 4.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.28 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.02 | 3.6% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $17.78 | 3.3% | 1 | 2025 |
| ADMA BioManufacturing LLC | Unresolved — no canonical attribution shown | $17.35 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.27 | 2.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.11 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $517.43 | 24 |
| Consulting Fee | $17.35 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $124.15 | 5 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $124.15 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $54.46 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $53.10 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $50.14 | 2 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $38.99 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $38.69 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.16 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xembify xembify |
2025 | Xembify | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Xembify open payments reported associated product |
CMS Open Payments — General Payments 5209 supporting records · 2197 recipient NPIs · example record 1249529389 |
Xembify · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 36 |
| Methylprednisolone | Methylprednisolone | 139 | 100 |
| Metformin Hcl | Metformin Hcl | 134 | 29 |
| Gabapentin | Gabapentin | 129 | 36 |
| Lisinopril | Lisinopril | 121 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 116 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 27 |
| Trazodone Hcl | Trazodone Hcl | 98 | 17 |
| Losartan Potassium | Losartan Potassium | 97 | 29 |
| Alprazolam | Alprazolam | 93 | 23 |
| Azithromycin | Azithromycin | 87 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 23 |
| Tramadol Hcl | Tramadol Hcl | 83 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 21 |
| Cefuroxime | Cefuroxime Axetil | 75 | 47 |
| Sertraline Hcl | Sertraline Hcl | 73 | 18 |
| Simvastatin | Simvastatin | 71 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 49 |
| Donepezil Hcl | Donepezil Hcl | 68 | 16 |
| Celecoxib | Celecoxib | 67 | 21 |
| Montelukast Sodium | Montelukast Sodium | 64 | 14 |
| Famotidine | Famotidine | 62 | 14 |
| Clonazepam | Clonazepam | 60 | 11 |
| Glimepiride | Glimepiride | 60 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 19 |
| Omeprazole | Omeprazole | 57 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 51 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 12 |
| Eliquis | Apixaban | 50 | 11 |
| Lorazepam | Lorazepam | 50 | 16 |
| Synthroid | Levothyroxine Sodium | 49 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 47 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 11 |
| Allopurinol | Allopurinol | 42 | 13 |
| Meloxicam | Meloxicam | 42 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 28 |
| Ondansetron Odt | Ondansetron | 39 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 36 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 33 |
| Azelastine Hcl | Azelastine Hcl | 37 | 18 |
| Carvedilol | Carvedilol | 36 | 11 |
| Ozempic | Semaglutide | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Xtampza Er | Oxycodone Myristate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Invokana | Canagliflozin | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Metronidazole | Metronidazole | 21 | 14 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Cefdinir | Cefdinir | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Xembify | Immune Globulin,gamma(Igg)klhw | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $534.78 · 25 records | PFIZER INC. | ALVESCO, CUTAQUIG, EVENITY, FARXIGA, GEMTESA, HORIZANT, KISUNLA, LEQVIO, MOUNJARO, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, REXULTI, Sunosi, VRAYLAR, XYOSTED, Xembify, Xhance, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error